# Ara A. Vaporciyan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ara-a-vaporciyan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,417 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 81 |
| i10-index | 270 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5049826084 |
| ORCID iD | https://orcid.org/0000-0002-2060-3584 |
| Works | 668 |

## Researcher papers

- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC](https://scholariq.org/papers/comutations-and-krasg12c-inhibitor-efficacy-in-advanced-nsclc/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.